Meeting
2022 ASCO Genitourinary Cancers Symposium
Association between biomarkers and clinical outcomes of lenvatinib + pembrolizumab in advanced renal cell carcinoma (RCC): Results from Study 111/KEYNOTE-146.
Authors
Chung-Han Lee
Memorial Sloan Kettering Cancer Center, New York, NY
Chung-Han Lee , Drew W. Rasco , Arpit Rao , Matthew H. Taylor , James J Hsieh , Alvaro Pinto , Nicholas J. Vogelzang , Z. Alexander Cao , Leah Suttner , Andrey Loboda , Amir Vajdi , Raluca Andreia Predoiu , Michael Nebozhyn , Jared Lunceford , Rodolfo F. Perini , Junji Matsui , Yukinori Minoshima , Corina E. Dutcus , Lea Dutta , Robert J. Motzer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Clinical Trial Registration Number
NCT02501096
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 375)
DOI
10.1200/JCO.2022.40.6_suppl.375
Abstract #
375
Poster Bd #
H8
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Genomic biomarkers of response to lenvatinib/pembrolizumab (Len/Pembro) in patients with advanced renal cell carcinoma.
First Author: Chung-Han Lee
Poster
2022 ASCO Annual Meeting
Association between tumor mutational burden (TMB) and mutational profile and its effect on overall survival: A post hoc analysis of patients with TMB-high and TMB-low metastatic cancer treated with immune checkpoint inhibitors (ICI).
First Author: Camila Bragança Xavier
Poster
2024 ASCO Annual Meeting
Matched tissue and circulating tumor DNA (ctDNA) analysis in renal cell carcinoma (RCC): Results from a multimodal real-world database.
First Author: Rana R. McKay
Poster
2023 ASCO Annual Meeting
PLUME: A single-arm phase II trial evaluating the combination of pembrolizumab and lenvatinib in metastatic uveal melanoma (mUM) patients (pts) previously treated or not with tebentafusp.
First Author: Manuel Rodrigues